Edward van der Horst
Chief Tech/Sci/R&D Officer at SENSEI BIOTHERAPEUTICS, INC.
Net worth: 35 445 $ as of 2024-04-29
Profile
Edward van der Horst is currently the Chief Scientific Officer at Sensei Biotherapeutics, Inc. He previously worked as the Senior Director-Preclinical Development at Igenica Biotherapeutics, Inc. from 2010 to 2017 and as the VP-Discovery Biology & Preclinical Drug at Zenith Epigenetics Ltd.
from 2017 to 2019.
Dr. van der Horst obtained a graduate degree from Ludwig-Maximilians-Universität München and a doctorate degree from Max Planck Institute of Biochemistry.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-14 | 35,445 ( 0.14% ) | 35 445 $ | 2024-04-29 |
Edward van der Horst active positions
Companies | Position | Start |
---|---|---|
SENSEI BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-12-06 |
Former positions of Edward van der Horst
Companies | Position | End |
---|---|---|
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Corporate Officer/Principal | 2019-07-31 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | 2016-12-31 |
Training of Edward van der Horst
Ludwig-Maximilians-Universität München | Graduate Degree |
Max Planck Institute of Biochemistry | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Commercial Services |
Sensei Biotherapeutics, Inc. |
- Stock Market
- Insiders
- Edward van der Horst